Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T for Refractory Autoimmune Diseases
NCT07161193Phase 2Not yet recruiting
- Sponsor
- Senlang Bio
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 CAR-T cells in systemic lupus erythematosus (SLE), pemphigus, idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Senlang Bio. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)pemphigusidiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07161193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07161193.